Oslo  (Norway), 17 October 2018 - Exercise  of employee share options, mandatory
notification  of  trade  and  resolution  to  increase  the share capital in PCI
Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade on 17 October 2018
Participants  in the  Company's share  option program  have on  17 October 2018
exercised  a total number  of 170,000 share options.  Out of these share options
85,000 were  exercised at a strike price  of NOK 9.08, 60,000 share options were
exercised  at a strike price of NOK 3.26 and 25,000 share options were exercised
at a strike price of NOK 7.81.

Out  of the total number  of exercised share options,  70,000 share options at a
strike price of NOK 9.08 and 15,000 share options at a strike price of NOK 7.81
are exercised by the primary insider Gaël L'Hévéder (CBDO), who has sold 33,000
shares  in the  market at  an average  price of  NOK 27.58 per share in order to
finance  the  cash  and  tax  impact  of  the  share  option exercise. After the
transaction  Mr. L'Hévéder  hold 62,000 shares  and 21,000 share  options in the
Company.

This  announcement also represents  a mandatory notification  of trade, which is
submitted by the Company on behalf of the primary insider.

2.   Resolution to increase the share capital
Following  the exercise of share options on 17 October 2018, the Company's Board
of  Directors,  pursuant  to  an  authorisation  granted by the Company's Annual
General  Meeting on May  29th 2018, has decided to  increase the Company's share
capital  with NOK 510,000 by issuing 170,000 new shares, each share of par value
NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK
111,494,670 divided  into 37,164,890 shares,  each with  a nominal  value of NOK
3.00 and  each giving  one vote  at the  Company's general  meeting. The capital
increase will result in gross proceeds of NOK 1,163,400.

Contact information:
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
